Better Health,
Brighter Future
Retail Investor Resource Hub
Takeda Stories
Takeda Highlights
Global
biopharmaceutical company
with presence in approx.
80 countries
and regions
Approx.
$29.4BN1 USD revenue
in FY2021
Planned R&D investment of
approx.
$4.7BN1 USD
in FY2022 to support
our innovative pipeline
Approx. 40 new molecular
entities (NMEs)
in the pipeline
Including 10 late-stage
development programs
Ranked
6th overall
in the 2021 Access to
Medicine (AtM) Index
Industry leader in
"Governance of Access"
Named
Global Top Employer
for five
consecutive years
Achieved
Carbon neutrality
in value chain in FY2020
On track for carbon zero
status by 2040
Targeting
2x (i.e. "low-twos")
Net Debt / Adjusted
EBITDA2 ratio in
FY2021-FY2023
Best-in-class
governance
Board comprising
15 experienced global leaders,
including 11 independent
external directors3
Stock Information
As of March 2022. References: FY2021 Investor Presentation; Corporate Overview
1USD included for reference, calculated at JPY/USD of 121.44
2Non-IFRS measure. Further information on this and other Takeda Non-IFRS measures is posted on Takeda’s investor relations website
3As defined by Tokyo Stock Exchange Securities Listing Regulations
Investor Events
Check back for event calendar updates or sign up for email alerts straight to your inbox.
Featured
Takeda has published its 2022 Annual Integrated Report
Find out how our financial and other impacts are creating value in the short, medium and long term, and the focus areas we believe are most important for the stakeholders and communities we serve. READ MORE
Innovation at Takeda
Our world-class R&D engine is focused on developing medicines and vaccines that will have a lasting impact on society and can make a critical difference to the lives of patients with limited or no options for treatment.
Frequently Asked Questions
General Information
Our 146th Ordinary General Meeting of Shareholders was held on June 29, 2022. Please visit our Annual Shareholders Meeting page for more information.
You may contact a licensed stockbroker or go through any registered broker-dealer to purchase shares of Takeda.
Takeda’s common shares are traded on the Tokyo Stock Exchange using stock code “4502.” Our ADSs are traded on the New York Stock Exchange using the symbol “TAK”.
An American Depositary Receipt (ADR) is a certificate representing ownership of American Depositary Shares (ADSs) in a non-U.S. corporation. They include the right to attend and vote at AGMs, the receipt of dividends, and other common shareholder rights. One ADS represents 0.5 shares of Takeda’s common stock.
Click here to learn more about Takeda’s historic share price performance.
Takeda’s largest shareholders and other share data, as most recently reported, can be found here.
Dividend Information
Takeda has maintained a well-established dividend policy of 180 yen per share annually. Information on historical dividends paid by Takeda can be found here
Takeda’s dividend payments have historically been issued on a semi-annual basis in June and December. The record date for year-end dividends is March 31 of each year. The record date for interim dividends is September 30 of each year.
Financial Information
Takeda’s fiscal year ends on March 31st. You can find our earnings materials and dates on our financial results webpage.
Takeda’s official reporting currency is the yen.
Takeda follows the International Financial Reporting Standards, or IFRS, for its financial reporting.
For historic financial highlights of Takeda, please refer to our Financial Highlights page.
Additional Information
To send a comment or question to Takeda Pharmaceutical Company Limited, please visit: https://www.takeda.com/who-we-are/contact-us/
To subscribe to email alerts from Takeda, please use the form at the top of this page.
For feedback or inquiries, please visit https://www.takeda.com/who-we-are/contact-us/